Introduction {#Sec1}
============

Available international guidelines for heart failure (HF) with reduced ejection fraction (HFrEF) recommend the following pharmacological therapies: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) if the patient is intolerant to ACEIs, beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), ivabradine and sacubitril--valsartan \[[@CR1]--[@CR3]\]. Although the implementation of clinical guidelines generally takes time, we have witnessed a gradual improvement and increased adherence to treatment with ACEIs/ARBs, BBs, and MRAs across different countries in the past two decades \[[@CR4]--[@CR8]\]. For example, the prescription of BBs has increased in Europe from 37% in 2000 to 87--91% today \[[@CR6]--[@CR8]\]. However, for newer drugs, such as ivabradine, implementation has been slower. For instance, Dierckx et al. reported that of patients with HFrEF, 94% were treated with BBs and only 4% were taking ivabradine \[[@CR9]\]. One possible reason is physician-related factors, such as lack of awareness of and/or adherence to optimal heart rate (HR) control as part of the treatment goal in HFrEF and sinus rhythm. Lack of adherence has previously been suggested as one contributing factor for suboptimal HF care \[[@CR10]--[@CR13]\]. Another reason is assumed to be due to differences in use of BBs between Sweden and other countries. BBs are frequently used in the treatment of HFrEF in Sweden and could, therefore, contribute to better HR control and hence decrease the indication for further HR reduction with ivabradine. At present, while prescriptions of BBs are largely similar between Sweden and rest of the world \[[@CR7], [@CR14]\], the mean doses of BBs were higher in Sweden than those in other countries \[[@CR6]--[@CR10], [@CR14]\]. According to the Swedish Heart Failure Registry (SwedeHF, *n* = 69,527, mean age 75 years), 67% of the patients with HFrEF were treated with BBs at ≥50% of the target doses. Among those \<65 years, 77% of male and 68% of female patients were at ≥50% of the target doses \[[@CR14]\]. However, according to the QUALIFY global registry, only 52% of HFrEF patients (mean age 63 years) were treated with BBs in ≥50% of the target doses \[[@CR9]\]. Therefore, lower use of ivabradine in Sweden was assumed to be related to the more effective use of BBs.

The survey of HR in patients with HF in Sweden (HR-HF) was an investigator-initiated, prospective, multicenter, observational longitudinal study designed to investigate the status of HR control in an outpatient cohort of stable patients with HFrEF compared with patients with HF and mid-range ejection fraction (HFmrEF) and HF with preserved ejection fraction (HFpEF) in both sinus rhythm and AF. Moreover, we explored underlying reasons to suboptimal HR control.

The main objective of the study was to assess awareness of an adherence to HR control among physicians, particularly as it contributed to the use of BBs (prescription and doses). We hypothesized that a substantial proportion of patients would have HRs above 70--75 bpm.

Materials and methods {#Sec2}
=====================

Protocol of the HR-HF study {#Sec3}
---------------------------

The HR-HF study was a prospective, multicenter, observational longitudinal survey of HF outpatients that included 734 patients in 27 centers in Sweden. These centers were hospital HF outpatient clinics with either dedicated HF nurse specialists or general practitioners. Eligible patients were those with established HF in an outpatient setting and considered on stable HF medication regimens.

The survey was carried out from 2014 to 2016 with a planned follow-up from 2017. The following variables were recorded as baseline data: demographics, diagnostic validation with left ventricular ejection fraction (LVEF), N-terminal pro-b-type natriuretic peptide (NT-pro-BNP) or B-type natriuretic peptide (BNP), hospitalizations due to HF in the past 2 years, cardiovascular risk factors, cardiovascular diseases, non-cardiovascular diseases, symptoms (breathlessness, tiredness and chest pain, Likert scale), blood pressure (sitting, standing, lying), HF and rhythm (by ECG), New York Heart Association (NYHA) functional class, ADL (activity of daily living), use of BBs (up-titration, ≥50% of the target dose, target dose or above target dose, reasons for not being on BB treatment, reasons for not achieving target dose, side effects), use of ACEIs/ARBs/MRAs (up-titration, dose, reasons for not on treatment, reasons for not achieving target dose, side effects), other pharmacologic treatments, cardiac resynchronization therapy (CRT) device, implantable cardioverter defibrillator (ICD) device, and physicians' judgment regarding actual HR.

Different from most available HF registries \[[@CR6]--[@CR8], [@CR14]\], the HR-HF survey focused on stable HF patients and only in outpatient settings with a special interest in HF control. Further, there was a dedicated focus on collecting information that might influence HF, for example, comorbidities and their gradings, symptoms and gradings, blood pressure, medications (prescriptions, dose, tolerability, side effects), and clinical judgment in relation to HF.

This study adhered to the guidelines available for human studies, including an approved ethical permit, which complies with the Helsinki Declaration and the International Ethical Guidelines for Good Clinical Practice. The study was approved by the Regional Ethical Review Board at the University of Gothenburg.

Study population {#Sec4}
----------------

Patients eligible for entry into the survey were outpatient adults (\>18 years old) with a well-established diagnosis of HF based on the latest European Society of Cardiology guidelines \[[@CR1], [@CR3]\] and according to the responsible investigator's clinical judgment; an abnormal echocardiography investigation that was congruent with the HF diagnosis; optimal treatment (physicians decision) and are, therefore, not planned for further up-titration; and a stable HF condition and plans for further outpatient follow-up. The LVEF cutoffs used to define HFrEF, HFmrEF, and HFpEF were \<40, 40--49, and ≥50%, respectively. No exclusion criteria were applied, except for those who did not or could not provide informed consent.

Baseline evaluation and data management {#Sec5}
---------------------------------------

Data were collected centrally using a case report form that was sent to the data management center, where checks for completeness, internal consistency, and accuracy were run. Forty-nine patients were excluded from the database because of protocol deviations or incompleteness.

Statistical analysis {#Sec6}
--------------------

For categorical variables, *n*(%) was presented. For continuous variables, mean (SD)/median (Min/Max/*n*) was presented. For comparison between the three EF groups, the Mantel--Haenszel Chi-square statistic was used for ordered categorical variables, the Chi-square test for non-ordered categorical variables, and the Jonckheere--Terpstra test for continuous variables. For comparison between groups in different HRs, Fisher's exact test (lowest one-sided *p* value multiplied by 2) was used for dichotomous variables, the Mantel--Haenszel Chi-square test for ordered categorical variables, and the Mann--Whitney *U* test for continuous variables. For interaction and subgroup analyses in reaching a HR \> 70 bpm, logistic regression was performed and odds ratios (ORs) with associated 95% confidence intervals (CIs) and *p* values are presented from these analyses.

All tests were two-tailed and *p* values \<0.05 were considered significant. All analyses were performed using SAS software version 9.4 (Cary, NC, USA).

Results {#Sec7}
=======

Patient characteristics in the overall cohort {#Sec8}
---------------------------------------------

Patient demographics, cardiovascular risk factors, cardiovascular diseases, non-cardiovascular diseases, clinical status, medications, and clinical assessment are outlined in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Briefly, despite that patients with HFrEF were more often male, had more ischemic heart disease, higher NT-pro-BNP, more ventricular extrasystolic couplets (VECs)/ventricular tachycardia (VT), lower blood pressure, and more left bundle branch block (LBBB), they had a similar number of non-cardiovascular co-morbidities compared with HFmrEF and HFpEF.Table 1Baseline data for demographics, risk factors, and medical historiesVariableTotal (*n* = 734)HFrEF (*n* = 425)HFmrEF (*n* = 187)HFpEF (*n* = 122)*p* valueDemographics Age (years)69.1 (11.6)\
70.6 (19.0; 95.3)69.8 (11.2)\
71.6 (19.0; 95.3)67.8 (12.3)\
69.8 (20.8; 89.8)68.7 (11.8)\
69.2 (30.0; 89.7)0.11 Male549 (74.8%)337 (79.3%)133 (71.1%)79 (64.8%)0.0004Cardiovascular risk factors Hypertension388 (52.9%)213 (50.1%)92 (49.2%)83 (68.0%)0.0033 BMI \>30 kg/m^2^209 (28.5%)121 (28.5%)48 (25.7%)40 (32.8%)0.57 Diabetes181 (24.7%)112 (26.4%)33 (17.6%)36 (29.5%)0.88 Hypercholesterolemia258 (35.3%)164 (38.9%)56 (29.9%)38 (31.4%)0.045 Stress179 (24.5%)98 (23.1%)53 (28.5%)28 (23.0%)0.66Cardiovascular diseases Ischemic heart disease339 (46.2%)218 (51.3%)82 (43.9%)39 (32.0%)0.0001 Primary valvular disease89 (12.1%)46 (10.8%)19 (10.2%)24 (19.7%)0.028 Cardiomyopathy243 (33.1%)152 (35.8%)57 (30.5%)34 (27.9%)0.067 Chronic persistent atrial fibrillation201 (27.4%)120 (28.2%)42 (22.5%)39 (32.0%)0.83 Paroxysmal atrial fibrillation119 (16.2%)68 (16.0%)24 (12.8%)27 (22.1%)0.28 VES/VT130 (17.7%)84 (19.8%)34 (18.2%)12 (9.8%)0.019Non-cardiovascular diseases Mild/moderate pulmonary disease70 (9.5%)43 (10.1%)15 (8.0%)12 (9.8%)0.73 Severe pulmonary disease13 (1.8%)7 (1.6%)3 (1.6%)3 (2.5%)0.61 GFR \<30 ml/min34 (4.7%)21 (5.0%)8 (4.3%)5 (4.1%) 30--60 ml/min257 (35.3%)163 (38.6%)51 (27.6%)43 (35.5%) \>60 ml/min437 (60.0%)238 (56.4%)126 (68.1%)73 (60.3%)0.14 Stroke without sequelae62 (8.4%)33 (7.8%)17 (9.1%)12 (9.8%)0.42 Stroke with sequelae23 (3.1%)15 (3.5%)5 (2.7%)3 (2.5%)0.48 Hemoglobin (g/L) (cat.) \<904 (0.6%)2 (0.5%)2 (1.2%)0 (0.0%) 90 to \<11029 (4.5%)22 (6.0%)3 (1.8%)4 (3.6%) ≥110611 (94.9%)342 (93.4%)161 (97.0%)108 (96.4%)0.14Depression81 (11.0%)47 (11.1%)20 (10.7%)14 (11.5%)0.95Impotence140 (29.3%)93 (32.0%)35 (28.2%)12 (19.0%)0.046Malignancy (active)15 (2.0%)9 (2.1%)4 (2.1%)2 (1.6%)0.78Malignancy (stable)73 (9.9%)45 (10.6%)13 (7.0%)15 (12.3%)0.98Malnutrition24 (3.3%)16 (3.8%)5 (2.7%)3 (2.5%)0.40Liver failure6 (0.8%)3 (0.7%)1 (0.5%)2 (1.6%)0.42Thyroid disease60 (8.2%)28 (6.6%)17 (9.1%)15 (12.3%)0.037Gout97 (13.2%)64 (15.1%)15 (8.0%)18 (14.8%)0.39Dementia3 (0.4%)2 (0.5%)1 (0.5%)0 (0.0%)0.56Other important non-cardiovascular disease65 (8.9%)32 (7.5%)14 (7.5%)19 (15.6%)0.018 Table 2Baseline data for clinical status, medication, and clinical assessment by physiciansVariableTotal (*n* = 734)HFrEF (*n* = 425)HFmrEF (*n* = 187)HFpEF (*n* = 122)*p* valueClinical status LVEF (%)36.9 (17.9)\
35.0 (10.0; 401.0)\
*n* = 73428.2 (6.8)\
30.0 (10.0; 39.0)\
*n* = 42543.0 (2.8)\
42.5 (40.0; 49.0)\
*n* = 18757.7 (31.7)\
55.0 (50.0; 401.0)\
*n* = 122\<.0001 NT-pro-BNP (ng/L)2810 (5044)\
1251 (10; 70,000)\
*n* = 6293255 (5345)\
1559 (10; 70,000)\
*n* = 3642021 (3936)\
808 (37; 30,000)\
*n* = 1562456 (5291)\
706 (43; 35,000)\
*n* = 109\<.0001 Sitting systolic blood pressure (mmHg)126.2 (58.2)\
120.0 (54.0; 1500.0)\
*n* = 619121.8 (17.8)\
120.0 (54.0; 190.0)\
*n* = 341126.1 (18.0)\
126.0 (85.0; 180.0)\
*n* = 170140.2 (133.4)\
126.5 (85.0; 1500.0)\
*n* = 1080.0010 Heart rate (bpm) by ECG68.4 (12.4)\
67.0 (34.0; 123.0)\
*n* = 73469.8 (13.0)\
68.0 (34.0; 123.0)\
*n* = 42565.5 (10.7)\
64.0 (43.0; 95.0)\
*n* = 18768.1 (12.0)\
66.0 (44.0; 103.0)\
*n* = 1220.0062  \<60 bpm163 (22.2%)81 (19.1%)56 (29.9%)26 (21.3%)  60--70 bpm298 (40.6%)166 (39.1%)77 (41.2%)55 (45.1%)  \>70 bpm273 (37.2%)178 (41.9%)54 (28.9%)41 (33.6%)0.019 LBBB163 (22.2%)111 (26.2%)37 (19.8%)15 (12.3%)0.0007 Sinus rhythm (and not previously detected persistent or paroxysmal atrial fibrillation)387 (52.8%)216 (50.9%)115 (61.5%)56 (45.9%)0.96 Atrial fibrillation (or previously detected persistent or paroxysmal)322 (43.9%)191 (45.0%)66 (35.3%)65 (53.3%)0.51 Chamber pacing149 (20.3%)105 (24.8%)26 (13.9%)18 (14.8%)0.0020 NYHA (cat.)  I--II538 (73.3%)301 (70.8%)150 (80.2%)87 (71.3%)  III--IV196 (26.7%)124 (29.2%)37 (19.8%)35 (28.7%)0.37Medication Beta-blockers705 (96.0%)411 (96.7%)176 (94.1%)118 (96.7%)0.62 RAAS (ACEI/ARB)707 (96.3%)413 (97.2%)180 (96.3%)114 (93.4%)0.065 MRA407 (55.4%)257 (60.5%)93 (49.7%)57 (46.7%)0.0017 Loop diuretics420 (57.2%)267 (62.8%)84 (44.9%)69 (56.6%)0.015 Digitalis96 (13.1%)61 (14.4%)14 (7.5%)21 (17.2%)0.96 Statin417 (56.8%)260 (61.2%)97 (51.9%)60 (49.2%)0.0062 Ivabradine/procoralan21 (2.9%)12 (2.8%)8 (4.3%)1 (0.8%)0.50Device treatments Conventional pacemaker63 (8.6%)29 (6.8%)16 (8.6%)18 (14.8%)0.0091 CRT106 (14.4%)85 (20.0%)15 (8.0%)6 (4.9%)\<.0001 ICD140 (19.1%)110 (25.9%)19 (10.2%)11 (9.0%)\<.0001Clinical assessment Physician considers patient having too low heart rate21 (2.9%)12 (2.8%)6 (3.2%)3 (2.5%)0.92 Physician considers patient having optimal heart rate568 (77.4%)320 (75.3%)152 (81.3%)96 (78.7%)0.22 Physician considers patient having too high heart rate145 (19.8%)93 (21.9%)29 (15.5%)23 (18.9%)0.22

Medications in the overall cohort {#Sec9}
---------------------------------

There were no differences in the use of BBs and ACEIs/ARBs between the groups of HF patients, regardless of EF, with 94--97% of the patients on treatment with BBs and 93--97% on treatment with ACEIs/ARBs (Table [2](#Tab2){ref-type="table"}). However, in patients with HFrEF more patients were treated with MRAs, diuretics, statins, and therapy devices (CRT, ICD). In addition, patients with HFrEF were well treated with BBs (97%), ACEIs/ARBs (97%), MRAs (61%), CRT (20%), ICD (25) 9%, whereas only 2.8% had ivabradine.

Concerning doses of BBs, these were similar in HFrEF, HFmrEF, and HFpEF. Percentage of achieved target dose ≥50% was 79% for HFrEF, 75% for HFmrEF, and 85% for HFpEF. For reached target dose, it was 43% for HFrEF, 45% for HFmrEF, and 44% for HFpEF. Moreover, 6% (HFrEF), 5% HFmrEF, and 5% (HFpEF) of the patients had a dose above the target dose.

The main reasons why patients with HFrEF were not on treatment with BBs (3%) were low blood pressure (22.6%), bradycardia (15.9%), fatigue (9.6%), and dizziness (9.6%). Despite that, about 97% of the patients were on treatment with BBs (only 60.6% did not report side effects). The most frequently reported side effects were tiredness (20%), cold extremities (8.8%), impotence (8.3%), nightmares (3.2%), and depression (3.2%).

Distribution of HR in the overall cohort {#Sec10}
----------------------------------------

In the total cohort HR was 68.4 ± 12 bpm with 37.2% of the patients having a HR \>70 bpm and 22.2% \<60 bpm (Table [2](#Tab2){ref-type="table"}). Patients with HFrEF presented the highest HR (69.8 ± 13 bpm): 41.9% \>70 bpm and HFpEF (68.1 ± 12): 33.6% \>70 bpm. Patients with HFmrEF had the lowest HR (65.5 ± 11), in which 28.9% had \>70 bpm (Table [2](#Tab2){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}). On average, atrial fibrillation (AF), irrespective of HFrEF, HFmrEF, and HFpEF, had a higher HR and more than 40% of the patients had a HR \>70 bpm as compared with sinus rhythm (about 30% of the patients had a HR \>70 bpm). A similar pattern was seen in HFrEF in which about 50% of those suffering from AF had a HR \>70 bpm, whereas 34% of those with sinus rhythm had a HR \>70 bpm. The pattern of HR remained similar between sinus rhythm and AF in HFrEF despite treatment with BBs (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Distribution of heart rate for patients with sinus rhythm and EF \<40% (**a**), EF 40--49% (**b**), and EF ≥50% (**c**) Fig. 2Distribution of heart rate in patients with EF \<40%

Clinical assessment by physician in the overall cohort {#Sec11}
------------------------------------------------------

Despite that 37% of all HF and 42% of all HFrEF had a HR \>70 bpm, 75% of the physicians felt that the patients had optimal HR control, whereas 20% considered the patients to have a HR that was too high.

HR and influencing factors in HFrEF with sinus rhythm {#Sec12}
-----------------------------------------------------

In HFrEF patients with sinus rhythm 33.6% had a HR \>70 bpm. As shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}, when all variables (demographic variables, cardiovascular risk factors, cardiovascular diseases, non-cardiovascular diseases, clinical status, medications, and clinical assessment by physicians) were compared between HR \<70 bpm and \>70 bpm, only a few of these variables were statistically significant: EF, symptoms of breathlessness and chest pain, and physicians' clinical assessment, i.e., those HFrEF patients with HR \>70 bpm had lower EF, were more symptomatic, and that 49% of the physicians considered a HR \>70 bpm optimal, whereas an equal number of physicians felt that a HR \>70 bpm was too high (but without further action) (Table [4](#Tab4){ref-type="table"}).Table 3Comparison of demographics, risk factors, and medical histories for HR ≤70 vs. \>70 bpm in all patients with sinus rhythm and EF \<40% (HFrEF)Variable≤70 bpm (*n* = 143)\>70 bpm (*n* = 73)*p* valueAge (years)67.5 (11.9)\
68.8 (25.5; 95.3)\
*n* = 14363.9 (14.2)\
65.8 (19.0; 91.0)\
*n* = 730.068Male107 (74.8%)57 (78.1%)0.72LVEF (%)29.1 (6.4)\
30.0 (10.0; 39.0)\
*n* = 14325.6 (7.7)\
25.0 (10.0; 38.0)\
*n* = 730.0016NT-pro-BNP (ng/L)2451 (3429)\
1360 (14; 25,600)\
*n* = 1183101 (4981)\
1239 (81; 27,362)\
*n* = 660.94Hemoglobin (g/L)137.4 (16.1)\
139.0 (86.0; 175.0)\
*n* = 123137.9 (23.7)\
140.0 (4.0; 178.0)\
*n* = 630.56Number of hospitalizations due to heart failure in the past 2 years0.427 (0.622)\
0.000 (0.000; 3.000)\
*n* = 1430.616 (0.860)\
0.000 (0.000; 3.000)\
*n* = 730.18Cardiovascular risk factors Hypertension69 (48.3%)30 (41.1%)0.39 BMI \>30 kg/m238 (26.6%)28 (38.4%)0.11 Smoking  Never smoked62 (43.4%)27 (37.0%)  Stopped smoking58 (40.6%)36 (49.3%)  Smoking23 (16.1%)10 (13.7%)0.70  Diabetes36 (25.2%)21 (28.8%)0.68 Alcohol  Normal consumption115 (93.5%)56 (96.6%)  Previously problematic5 (4.1%)2 (3.4%)  Problematic3 (2.4%)0 (0.0%)0.28  Heredity32 (22.4%)26 (36.6%)0.043  Hypercholesterolemia59 (41.3%)22 (30.6%)0.17  Stress33 (23.2%)22 (30.1%)0.35Cardiovascular diseases Ischemic heart disease81 (56.6%)31 (42.5%)0.067 Primary valvular disease12 (8.4%)5 (6.8%)0.92 Cardiomyopathy46 (32.2%)26 (35.6%)0.72 Myocarditis3 (2.1%)1 (1.4%)1.00 Chronic persistent atrial fibrillation0 (0.0%)0 (0.0%)1.00 Paroxysmal atrial fibrillation0 (0.0%)0 (0.0%)1.00 Cardiac arrest10 (7.0%)1 (1.4%)0.13 VES/VT28 (19.6%)14 (19.2%)1.00 SVT3 (2.1%)4 (5.5%)0.35 Bradycardia14 (9.8%)5 (6.8%)0.65Non-cardiovascular diseases Mild/moderate pulmonary disease15 (10.5%)6 (8.2%)0.79 Severe pulmonary disease0 (0.0%)3 (4.1%)0.075 Asthma7 (4.9%)4 (5.5%)1.00 GFR (cat.)  GFR \<30 ml/min3 (2.1%)2 (2.8%)  GFR 30--60 ml/min53 (37.3%)24 (33.8%)  GFR \>60 ml/min86 (60.6%)45 (63.4%)0.79  Missing12  Stroke without sequelae10 (7.0%)2 (2.7%)0.33  Stroke with sequelae5 (3.5%)1 (1.4%)0.68  Depression14 (9.8%)10 (13.7%)0.52  Impotence23 (23.5%)8 (16.7%)0.47  Malignancy (active)3 (2.1%)1 (1.4%)1.00  Malignancy (stable)15 (10.5%)8 (11.0%)1.00  Malnutrition1 (0.7%)2 (2.7%)0.53  Liver failure0 (0.0%)0 (0.0%)1.00  Thyroid disease10 (7.0%)2 (2.7%)0.33  Gout21 (14.7%)5 (6.8%)0.14  Dementia0 (0.0%)1 (1.4%)0.68  Other important non-cardiovascular disease13 (9.1%)8 (11.0%)0.83Current status Breathlessness---Likert scale  Never45 (31.5%)10 (13.7%)  Upstairs75 (52.4%)51 (69.9%)  On level ground20 (14.0%)7 (9.6%)  In the shower3 (2.1%)2 (2.7%)  When resting0 (0.0%)3 (4.1%)0.015 Tiredness---Likert scale  Never59 (41.3%)20 (27.4%)  Upstairs63 (44.1%)43 (58.9%)  On level ground15 (10.5%)5 (6.8%)  In the shower4 (2.8%)1 (1.4%)  When resting2 (1.4%)4 (5.5%)0.12 Chest pain---Likert scale  Never128 (89.5%)71 (97.3%)  Upstairs10 (7.0%)2 (2.7%)  On level ground2 (1.4%)0 (0.0%)  In the shower1 (0.7%)0 (0.0%)  When resting2 (1.4%)0 (0.0%)0.048 Sitting systolic blood pressure (mmHg)123.1 (15.8)\
120.0 (85.0; 165.0)\
*n* = 122123.4 (22.4)\
122.0 (54.0; 180.0)\
*n* = 600.94 Standing systolic blood pressure (mmHg)120.6 (17.6)\
120.0 (80.0; 165.0)\
*n* = 113121.8 (22.5)\
122.5 (70.0; 180.0)\
*n* = 580.80LBBB44 (30.8%)19 (26.0%)0.57NYHA I32 (22.4%)10 (13.7%) II81 (56.6%)44 (60.3%) III30 (21.0%)19 (26.0%)0.14 Table 4Medications and physicians' opinion regarding a HR ≤70 vs. \>70 bpm in patients with sinus rhythm and EF \<40%Variable≤70 bpm (*n* = 143)\>70 bpm (*n* = 73)*p* valueBeta-blockers138 (96.5%)70 (95.9%)1.00 Beta-blockers (name)  Atenolol1 (0.7%)0 (0.0%)  Bisoprolol53 (37.1%)31 (42.5%)  Carvedilol12 (8.4%)2 (2.7%)  Metoprolol72 (50.3%)37 (50.7%)  Not using5 (3.5%)3 (4.1%)0.51 Reasons for not using BBs  Low blood pressure0 (0.0%)1 (1.4%)0.68  Dizziness1 (0.7%)1 (1.4%)1.00  Raynaud/Claudio0 (0.0%)1 (1.4%)0.68  Pulmonary disease0 (0.0%)0 (0.0%)1.00  Fatigue0 (0.0%)2 (2.7%)0.23  Bradycardia5 (3.5%)0 (0.0%)0.25  Asthma0 (0.0%)0 (0.0%)1.00  Decompensation0 (0.0%)0 (0.0%)1.00  No indication0 (0.0%)0 (0.0%)1.00  Other1 (0.7%)1 (1.4%)1.00 BB dose reached  ≥50 target dose^a^99 (72.8%)56 (80.0%)0.34  Target dose^a^52 (38.2%)28 (40.0%)0.92  \>Target dose^a^2 (1.5%)0 (0.0%)0.87  The maximum tolerated dose (physician´s opinion)129 (93.5%)59 (84.3%)0.066 Reasons for not achieving BB target dose  Low blood pressure32 (23.2%)15 (21.4%)0.92  Fatigue12 (8.7%)8 (11.4%)0.69  Dyspnea3 (2.2%)0 (0.0%)0.58  Dizziness11 (8.0%)9 (12.9%)0.38  Bradycardia30 (21.7%)3 (4.3%)0.0010  Other14 (10.1%)10 (14.3%)0.51 BB tolerated (on treatment with BB)  No report of side effects87 (60.8%)44 (60.3%)1.00  Nightmares as side effect5 (3.5%)2 (2.7%)1.00  Cold extremities as side effect16 (11.2%)3 (4.1%)0.13  Impotence as side effect16 (11.2%)2 (2.7%)0.049  Depression as side effect2 (1.4%)5 (6.8%)0.090  Tiredness as side effect26 (18.2%)17 (23.3%)0.48  Other side effects3 (2.1%)2 (2.7%)1.00 BB up-titration done at  Department of Cardiology110 (80.3%)59 (83.1%)  Department of Medicine22 (16.1%)11 (15.5%)  Primary care5 (3.6%)1 (1.4%)0.65 BB duration (years)3.60 (4.55)\
1.50 (0.00; 19.80)\
*n* = 1383.01 (4.31)\
1.30 (0.00; 18.10)\
*n* = 690.055RAAS140 (97.9%)69 (94.5%)0.35 ACE inhibitors92 (64.3%)44 (60.3%)0.66 ARB51 (35.7%)26 (35.6%)1.00 ACE inhibitors (name)  Enalapril24 (16.8%)19 (26.0%)  Lisinopril0 (0.0%)1 (1.4%)  Not using51 (35.7%)29 (39.7%)  Ramipril68 (47.6%)24 (32.9%)0.082 ARB (name)  Candesartan38 (26.6%)18 (24.7%)  Irbesartan0 (0.0%)2 (2.7%)  Losartan11 (7.7%)5 (6.8%)  Not using A92 (64.3%)47 (64.4%)  Valsartan2 (1.4%)1 (1.4%)0.40 ACE reached the maximum tolerated dose (physician's opinion)86 (93.5%)36 (81.8%)0.080 ARB reached the maximum tolerated dose (physician's opinion)43 (82.7%)23 (82.1%)1.00 RAAS reached the maximum tolerated dose (physician's opinion)125 (89.3%)56 (81.2%)0.16MRA84 (58.7%)42 (57.5%)0.98 MRA reached the maximum tolerated dose (physician's opinion)74 (88.1%)39 (92.9%)0.62Other treatments Loop diuretics79 (55.2%)40 (54.8%)1.00 Digitalis4 (2.8%)3 (4.1%)0.88 Statin94 (65.7%)42 (57.5%)0.30 Nitrate17 (11.9%)7 (9.6%)0.79 Other thrombin inhibitors26 (18.2%)16 (21.9%)0.63 ASA78 (54.5%)38 (52.1%)0.84 Anticoagulants25 (17.5%)12 (16.4%)1.00 Antiarrhythmics other than BB3 (2.1%)2 (2.7%)1.00 Ivabradine/procoralan3 (2.1%)6 (8.2%)0.084 Allopur/probenecid19 (13.3%)3 (4.1%)0.051 Device treatments  Conventional pacemaker3 (2.1%)6 (8.2%)0.084  CRT20 (14.0%)9 (12.3%)0.91  ICD28 (19.6%)18 (24.7%)0.49Clinical assessment Physician considers patient having too low heart rate4 (2.8%)1 (1.4%)0.90 Physician considers patient being optimally treated129 (90.2%)36 (49.3%)\<0.0001 Physician considers patient having too high heart rate10 (7.0%)36 (49.3%)\<0.0001^a^ Target dose is calculated only for patients using metoprolol (target = 200 mg), carvedilol (target = 50 mg), and bisoprolol (target = 10 mg)

Use of BBs in HFrEF with sinus rhythm {#Sec13}
-------------------------------------

As can be seen in Table [4](#Tab4){ref-type="table"}, there were no differences between a HR \<70 bpm and a HR \>70 bpm in the use of BBs, regardless of prescription, type of BBs, duration of BB use, site for BB up-titration, or dose. In HFrEF with sinus rhythm, BBs were used in 97% (HR \<70 bpm) and 96% (HR \>70 bpm) in overall population, and in 73% (HR \<70 bpm) and 80% (HR \>70 bpm) at ≥50% of target dose, 38% (HR \<70 bpm) and 40% (HR \>70 bpm) at target dose, and 2% (HR \<70 bpm) and 0% (HR \>70 bpm) at a dose above target dose (Table [4](#Tab4){ref-type="table"}).

Interaction analysis {#Sec14}
--------------------

Because the current study was aimed to explore possible contributing factors to a HR \>70 bpm in HFrEF with sinus rhythm, we analyzed the interaction with EF or BBs leading to the risk of a HR \>70 bpm. Low EF is a recognized factor linked to a HR \>70 bpm. BBs are assumed to impact HR. Interaction analyses were performed between EF and BBs vs. baseline data that included demographics, medical history, and clinical and laboratory data (Table [5](#Tab5){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}). There was no significant interaction with BBs but significant interactions between EF and the following variables as explanatory factors of HF \>70 bpm were observed: psychological stress, VPC/VT, GFR, and systolic blood pressure. In patients who had no stress, no VPC/VT, lower GFR, and lower SBP (\<100 mmHg), EF caused a lower risk for HR \>70 bpm, whereas in patients with stress and VPC/VT, higher GFR and higher SBP (\>140 mmHg) EF did not affect HR.Table 5Interaction analyses between LVEF (%) and beta-blockers vs. demographics and clinical and laboratory data in an explanatory analysis of HR ≤70 vs. \>70 bpm in all patients with sinus rhythm and EF \<40%Interaction tested with variable*p* value for interaction with LVEF*p* value for interaction with BBAge (years)0.810.55Sex0.190.96NT-pro-BNP (ng/L)0.120.57Hemoglobin (g/L)0.300.89Number of hospitalizations due to heart failure the past 2 years0.900.83Hypertension0.201.00BMI \>30 kg/m^2^0.760.95Smoking0.210.88Diabetes0.620.95Heredity0.150.95Hypercholesterolemia0.960.29Ischemic heart disease0.910.26Primary valvular disease0.690.97Cardiomyopathy0.380.23Cardiac arrest0.42VES/VT0.018SVT0.90Bradycardia0.500.92Mild/moderate pulmonary disease0.490.97Severe pulmonary disease1.00Asthma0.18GFR (cat.)0.0620.89Stroke without sequelae0.290.97Stroke with sequelae0.35Depression0.120.97Impotence0.170.95Malignancy (active)0.96Malignancy (stable)0.460.97Thyroid disease0.260.98Sitting systolic blood pressure (mmHg)0.140.76Sitting systolic blood pressure (cat.)0.1000.93Standing systolic blood pressure (mmHg)0.370.44Standing systolic blood pressure (cat.)0.630.49LBBB0.370.97Chamber pacing0.450.95NYHA0.440.27Married/partner0.620.93Working0.840.95Retired0.880.95 Fig. 3Subgroup analysis of the effect of LVEF on HR in patients with sinus rhythm

Discussions {#Sec15}
===========

This study reports suboptimal HR control in stable patients with HFrEF in an outpatient clinical setting. We also report the distribution of HR in different categories of HF: HFrEF, HFmrEF, and HFpEF, both in sinus rhythm and AF, which, to our knowledge, has not been previously reported.

The mean HR of the HFrEF patients in sinus rhythm was 70 bpm with 34% having \>70 bpm. This rate was lower than in our previous study (SwedeHF) in which about 47% of the patients had a HR \>70 bpm \[[@CR14]\]. However, there are several differences: first, the present study was a prospective investigation with a specific aim to study HR and, therefore, ECG was required to register HR at the time of inclusion; in SwedeHF the time point for HR could vary. Second, in the present study all HF patients were stable and in an outpatient clinical setting, whereas most of the patients in SwedeHF were hospitalized. However, the data from our current study were similar to another prospective multicenter study of patients with HFrEF and sinus rhythm in which 32% of the patients had HFs ≥70 bpm \[[@CR10]\].

Possible causes for suboptimal target heart rate in HFrEF and sinus rhythm {#Sec16}
--------------------------------------------------------------------------

Two reasonable questions to ask are: why does HR differ across different studies and why does a HR of \>70 bpm still occur in at least one-third of the HFrEF patients? As demonstrated in our study, non-achievement of the recommended target HR was unrelated to age, sex, cardiovascular risk factors, cardiovascular diseases, and comorbidities, but was related to EF and the clinical decision of the responsible physician. From our present and previous study \[[@CR14]\], it appears that EF has an important impact on HR (i.e., lower EF is associated with higher HR), possibly implying that left ventricular function is one of the essential driving factors for higher HR.

Clinical assessment by physicians has received increased attention related to their roles in optimizing HF care \[[@CR10]--[@CR13]\], reflecting the awareness of and adherence to guideline-recommended treatment goals. In our study almost half of the physicians regarded a HR \>70 bpm as optimal in HFrEF and sinus rhythm though equally many physicians considered a HR \>70 bpm as being too high but without any plan for immediate action.

Role of BBs for suboptimal target HR in HFrEF and sinus rhythm {#Sec17}
--------------------------------------------------------------

While the question of how BBs favorably influence the course of HF still remains unanswered, lowering HR is considered very important \[[@CR18], [@CR19]\]. Although an increasing number of studies have demonstrated that a substantial proportion of patients with HFrEF does not tolerate the target doses of BBs used in large clinical trials \[[@CR7], [@CR10], [@CR14], [@CR20]\], dose issues surrounding BB appear persistent: first, when could we be certain that patients have reached the highest tolerable dose despite being below target dose? Second, how long should dose up-titration continue until it is certain that patients have reached the highest dose tolerable? As long as these questions remain unanswered, the addition of HR-reducing therapies (such as ivabradine) will be postponed or questioned. Moran et al. argued that a lower use of BBs accounted for the difference between those attaining and those not attaining target HRs in stable HFrEF and sinus rhythm \[[@CR10]\]. However, these findings could not be confirmed in our study. We did not observe any differences in the use of BBs between patients that had \<70 bpm and those that had \>70 bpm, nor was there any interaction with BBs in patients with a HR \>70 bpm. Both prescription (96%) and achieved target doses (40%) of BBs were higher in our study than in the above-mentioned study (prescription 89% and achieved target doses 25%) \[[@CR10]\]. Taken together, these studies seem to suggest that despite differences in the use of BBs, a sizable proportion (approximately one-third) of the patients with HR \>70 bpm was similar, suggesting that use of BBs is not the only explanation. Indeed, the proportion of HR \>70 bpm is unrelated to the use of BBs as long as the BBs were up-titrated to the highest dose tolerable, which differs individually. As previously shown from the MERIT-HF trial, sicker patients did not tolerate higher doses of BBs, and despite this, the BBs were still effective, suggesting that it is the highest dose tolerable to patients that is all-important \[[@CR20]\]. Further, as suggested from a recent meta-analysis, BB efficacy was significant in sinus rhythm, but not in AF, even though both groups showed a reduction in HR \[[@CR21]\].

Limitations {#Sec18}
===========

The HF population enrolled in the study may not necessarily reflect the overall HF population. However, similar clinical characteristics in our study as compared with those from SwedeHF suggest the representativeness of our study population. Although participating investigators were encouraged to include patients consecutively we were unable to check that consecutive sampling was conducted.

Implications {#Sec19}
============

Our data, together with available data \[[@CR6]--[@CR10], [@CR14]\], underline that about one-third of the patients with HFrEF and sinus rhythm did not reach the target HR of \<70 bpm as recommended by HF guidelines. However, this cannot be attributed to the use of BBs as long as they are administered in the highest tolerable dose. Further, approximately two-thirds of these patients will not tolerate the target dose, which actually has never been confirmed in a real-world setting.

A possible reason why physicians chose not to add ivabradine when the HR was \>70 bpm might be that the recommendations from the EMA and most national pharmaceutical agencies are that ivabradine had an accepted indication if HR is \>75 bpm \[[@CR15]--[@CR17]\]. The reason for this discrepancy is that survival benefit was shown in the SHIFT study in a subgroup with a heart rate of 75 bpm or higher \[[@CR22]\]. Several observational studies have found an association between elevated HR and poor survival. Our study indicates that among patients with HFrEF, who were in sinus rhythm and on highest tolerable doses of beta-blockers, 14.3% might be eligible for ivabradine, which was similar to a previous study \[[@CR9]\].

Conclusion {#Sec20}
==========

In this prospective survey of patients with stable HF in an outpatient clinical setting, we observed suboptimal HR control in HFrEF with sinus rhythm that was unrelated to the use of BBs. Our results support the position that concerted efforts and greater attention to control of HR in patients with HFrEF and sinus rhythm are needed.
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